FDA Directors Defend User Fee Reauthorization as Senators Skewer the Agency

In a hearing of the Senate Committee on Health, Education, Labor and Pensions (HELP) yesterday, ranking member Sen. Richard Burr (R-N.C.) characterized the funding in the FDA’s reauthorization agreements as “double the money for mediocre performance.”
Source: Drug Industry Daily